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What are RASSF proteins? RASSF 
stands for Ras association domain 
family. This family represents a 
group of ten mammalian proteins 
that contain a Ras association (RA) 
domain (Figure 1A). The first member 
of this family was identified as a 
binding partner of the Ras oncoprotein 
and was named NORE1 (novel Ras 
effector 1; now called RASSF5). The 
hunt for tumor suppressor genes 
on chromosome 3p21.3, a locus 
frequently undergoing deletion or loss 
of heterozygosity in human cancer, 
led to the discovery of RASSF1 about 
a decade ago. Several additional 
family members, including RASSF-2, 
-3, -4 and -6, were soon identified. 
These first six RASSF proteins 
possess a carboxy-terminal domain 
termed the SARAH (Salvador-Rassf-
Hippo) domain, which is involved in 
homo/heterodimerization. RASSF 
proteins are devoid of any known 
enzymatic activity, and most likely 
function as scaffolds for larger 
multi- protein complexes. More recent 
additions to the RASSF family include 
RASSF7–RASSF10. These proteins 
differ from RASSF1–RASSF6 because 
they lack the SARAH domain, they 
have a lower degree of homology 
to the other members, and their RA 
domain is localised near the amino 
terminus. Among RASSF1–RASSF6, 
the highest similarity exists between 
RASSF-1, -3, and -5, which form 
one subgroup, probably derived 
from a common ancestor (related to 
T24F1.3 in Caenorhabditis elegans), 
and RASSF-2, -4 and -6, which form 
a second subgroup and are related 
to the dRASSF protein in Drosophila.  
Several of the RASSF genes encode 
different protein isoforms adding to the 
complexity of this family (Figure 1A).
What is the function of the 
RASSF proteins? The most 
well- characterized family members are 
RASSF1 and RASSF5. There is clear 
evidence that RASSF5 can bind to 
GTP-bound (active) Ras proteins. One 
Quick guide of its isoforms, RASSF5A, can engage a Ras-induced pro-apoptotic pathway. 
However, for many of the other family 
members it is not completely clear 
whether they really are endogenous 
binding partners of Ras proteins or 
perhaps of other small GTPases. 
For example, it was shown recently 
that RASSF1A interacts with the Ran 
GTPase, controlling microtubule 
stability and the integrity of the mitotic spindle. The cellular localization of 
most RASSF proteins is cytoplasmic, 
with a tendency of several of them, 
e.g. RASSF1 and RASSF5, to 
accumulate at spindle poles and 
to associate with the microtubule 
network. These proteins interact with 
microtubule-associated proteins 
and are important for microtubule 
stabilization and potentially for the 
regulation of mitosis.A
RASSF2
RASSF3
RASSF4
RASSF5A
RASSF6A
RASSF1C
RASSF5B
RASSF5C
79–187 187–234
122–170 274–336
RASSF6B
218–306 313–360
186–274 281–328
122–170 274–364 366–413
174–262 270–317
176–264 272–319
124–218 220–267
RASSF1A
51–101 194–288
RAC1 SARAH
290–337
6–89
RASSF7
RASSF8
1–82
RASSF9
25–119
RASSF10
112–241
121–211 213–260
340
270
326
238
321
418
336
265
337
369
373
392
435
615
Length
(aa)
B
MST1/2SAV1
RASSF1A LATS1/2MOB1
P
YAP
P
P
Pro-survival genes
TEAD
Current Biology
Figure 1. The RASSF family.
(A) Length (in amino acids, aa) and domain structure of the 10 human RASSF proteins. Yellow, 
C1 domain and putative diacylglycerol binding site; green, Ras association (RA) domain; blue, 
C-terminal SARAH domain. (B) Role of RASSF1A in the Hippo pathway as an activator of MST/
Hippo kinase. RASSF1A and SAV1 form complexes with MST1/2 and promote phosphoryla-
tion of the LATS1/2–MOB1 complex. The activated LATS kinases phosphorylate YAP, a binding 
partner of TEAD transcription factors, leading to inactivation of YAP.
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R345A large amount of experimental 
evidence points to a role of 
RASSF proteins in pro-apoptotic 
pathways. When these proteins 
are overexpressed, they can 
promote apoptotic cell death. The 
mechanism leading to apoptosis, 
again best studied for RASSF1 and 
RASSF5, often entails activation of 
the pro- apoptotic kinases MST1 
and MST2. Other studies identified 
RASSF1A and the protein MOAP-1 as 
important components linking death 
receptors to the apoptotic machinery.
What is the connection between 
RASSF proteins and the Hippo 
pathway? The aforementioned MST1 
and MST2 kinases have been shown 
by many labs to be binding partners 
of RASSF1–RASSF6 proteins. This 
interaction seems to be quite stable 
and robust; for example, MST1 and 
MST2 protein bands can be seen 
on Coomassie blue-stained gels 
after RASSF1A immunoprecipitation 
and these proteins are among the 
most abundant identified by mass 
spectrometry analysis of RASSF1A-
associated proteins. MST1 and MST2 
are the mammalian orthologues 
of the Drosophila Hippo kinase, a 
serine-threonine kinase that plays an 
essential role in a well- characterized 
pathway important for organ size 
control, cell proliferation and 
apoptosis, not only in flies but also 
in mammals. MST1/Hippo kinases 
activate the downstream kinase 
Warts in Drosophila, as well as the 
mammalian counterparts, LATS1 
and LATS2, and the related NDR1/2 
kinases. The LATS kinases promote 
inactivating phosphorylation and 
cytoplasmic sequestration of 
the Yorkie/YAP transcriptional 
coactivator, leading to reduced 
cell proliferation and increased 
apoptosis (Figure 1B). Since several 
of the RASSF proteins, most notably 
RASSF1A and RASSF5A, are at the 
top of this cascade, at least one of 
their physiological functions is likely 
to be the modulation of this pathway. 
RASSF1A has a positive (activating) 
effect on MST1/2 activity, but the 
Drosophila dRASSF protein and the 
related mammalian protein RASSF6 
have an inhibitory effect on  
Hippo/MST activity. 
Although MST kinases and the 
Hippo pathway are implicated in 
regulation of cell proliferation and 
apoptosis, other functions need to be characterized in more detail. It is 
notable that the yeast orthologues 
of MST and LATS kinases — Cdc15 
and Dbf2 — are essential for cell 
division and are components of the 
mitotic exit network. Evidence is 
accumulating that this also may be 
the case in mammalian systems, 
given that mitotic roles for MST1/2, 
LATS1/2, and RASSF1A have been 
reported. However, curiously, such 
evidence is currently lacking for the 
Drosophila Hippo pathway.
What is the role of RASSF proteins 
in tumorigenesis? The RASSF1 
gene is frequently inactivated by 
promoter hypermethylation in a 
variety of human tumors. In some 
human tumors, such as hepatocellular 
carcinoma and small cell lung 
cancer, between 80 and 100% of all 
tumors have inactivated RASSF1A. 
Mouse models of Rassf1a deficiency 
have confirmed its role as a tumor 
suppressor. The tumor-prone 
phenotype of Rassf1a-deficient 
mice can be rationalized in the 
context of the role of this protein as 
a pro- apoptotic factor, in particular 
as an activator of the Hippo pathway, 
although this remains to be proven. 
Several mouse models of Hippo 
pathway deficiency have now 
become available. Lats1-deficient 
mice develop soft-tissue sarcomas 
and ovarian tumors. Liver-specific 
deletion of both Mst1 and Mst2 (the 
constitutive double knockout is 
embryonic lethal) leads to aggressive 
hepatocellular carcinomas. This 
phenotype resembles that obtained 
by overexpression of the YAP 
oncogene, the protein product of 
which is negatively regulated by the 
Hippo pathway. In human tumors, YAP 
is often overexpressed and MST1/2 
as well as LATS1 can be silenced 
epigenetically. However, the most 
common aberration of the pathway in 
human tumors is epigenetic silencing 
of RASSF1A, and sometimes of other 
RASSF family members. 
Do RASSF proteins have other 
functions? The role of RASSF 
proteins outside of tumorigenesis, 
cell proliferation and apoptotic 
pathways has been less well 
investigated. However, recent 
studies point to a surprising role for 
RASSF1A in the regulation of cardiac 
function. Ablation of RASSF1A in 
mice significantly enhanced the hypertrophic response to transverse 
aortic constriction, leading to an 
increase in the heart weight:body 
weight ratio in Rassf1a-deficient 
mice. The shorter isoform of RASSF5, 
RASSF5C (also known as RAPL or 
NORE1B), has a role in lymphocyte 
adhesion and trafficking. Ongoing 
research will certainly uncover 
additional and probably unexpected 
functional roles of RASSF proteins.
What do we still need to learn? 
There are many aspects of RASSF 
function that require much further 
investigation. Mechanistic studies 
of how these proteins, in particular 
RASSF1–6, activate or inhibit the 
Hippo kinases need to be conducted. 
We do not know how RASSF proteins 
are mechanistically connected to the 
normal biological roles of Ras proteins 
or other small GTP-binding proteins 
during development or during the 
initiation of tumorigenesis. Although 
all members of the RASSF family 
contain an RA domain, by definition, 
the presence of this domain does not 
always guarantee that the protein is 
a direct binding partner of Ras. Aside 
from induction of apoptosis, which 
often involves non- physiological 
conditions, we need to understand 
how the RASSF proteins are regulated 
physiologically, and how they 
affect the activity of other proteins 
or pathway components in their 
assumed role as scaffolding proteins. 
Finally, we are only just beginning to 
understand the functions of the more 
recently discovered family members, 
RASSF7–RASSF10.
Where can I find out more?
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